An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
about
Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation.The current role of calcineurin inhibitors in posttransplant immunosuppression?Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Considerations in sirolimus use in the early and late post-transplant periods.mTOR inhibitor-associated dermatologic and mucosal problems.Late-onset invasive aspergillosis in organ transplant recipients in the current era.A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy.Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression.Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
P2860
Q33394258-1ED4FB03-3391-4D85-B1B2-D0FE6324191EQ36733784-64DE76EF-4A59-4145-B7C9-78249B7E64CDQ37064446-A6E9F218-1D41-471E-8574-0FBA2C9F9D2DQ37517602-C7C8404B-1843-456D-9556-528B2EBAC00DQ37710669-5C4563AD-36D1-4AB4-99CD-880B05FABCC2Q44405749-1BB74759-8D35-47D8-AE73-1CE945FE7E37Q46702756-8E5948BE-CFE5-42F8-9E7F-8FC6519F06D2Q46856408-4962647A-AD72-43D2-AF7C-F242DFD84AE9Q51101954-7ECC4026-1BAC-41B0-9B1F-10F2A0F8E8E5Q51788749-BA37B539-1F34-46EB-BE38-36387E10DE76Q53599876-E522CAD7-3B88-441B-98CD-71747E881EDDQ54572059-20BEBA73-7463-402E-9C55-FACD983DD67C
P2860
An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
An open-label, pilot study eva ...... moderate renal insufficiency.
@en
An open-label, pilot study eva ...... moderate renal insufficiency.
@nl
type
label
An open-label, pilot study eva ...... moderate renal insufficiency.
@en
An open-label, pilot study eva ...... moderate renal insufficiency.
@nl
prefLabel
An open-label, pilot study eva ...... moderate renal insufficiency.
@en
An open-label, pilot study eva ...... moderate renal insufficiency.
@nl
P2093
P2860
P1476
An open-label, pilot study eva ...... moderate renal insufficiency.
@en
P2093
David J Cohen
Flavio Vincenti
J Richard Thistlethwaite
John Pirsch
Mark Pescovitz
Scott H Adler
Stephen Jensik
V Ram Peddi
P2860
P304
P356
10.1111/J.1399-0012.2004.00314.X
P577
2005-02-01T00:00:00Z